The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …

BACKGROUND SARS-CoV-2–specific antibodies may protect from reinfection and disease,
providing rationale for administration of plasma containing SARS-CoV-2–neutralizing …

Background Characterizing the kinetics of the antibody response to severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2) is of critical importance to developing strategies …

Phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) is a lipid kinase involved in endosome
maturation that emerged from a haploid genetic screen as being required for Ebola virus (…

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing an exponentially
increasing number of coronavirus disease 19 (COVID-19) cases globally. Prioritization of …

Ebolaviruses cause an often rapidly fatal syndrome known as Ebola virus disease (EVD),
with average case fatality rates of ~50%. There is no licensed vaccine or treatment for EVD, …

The SARS-CoV-2 pandemic has made it clear that we have a desperate need for antivirals.
We present work that the mammalian SKI complex is a broad-spectrum, host-directed, …

Background Ebola virus (EBOV) mainly targets myeloid cells; however, extensive death of T
cells is often observed in lethal infections. We have previously shown that EBOV VP40 in …

As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic expanded,
it was clear that effective testing for the presence of neutralizing antibodies in the blood of …

Experimental vaccines for the deadly zoonotic Nipah (NiV), Hendra (HeV), and Ebola (EBOV)
viruses have focused on targeting individual viruses, although their geographical and bat …